What tests should I get after a Merkel Cell Carcinoma diagnosis

Tests After a Merkel Cell Carcinoma Diagnosis

After being diagnosed with Merkel cell carcinoma (MCC), your healthcare team will recommend several tests to understand your cancer's stage and characteristics. Here's what you should expect:

Initial Staging & Imaging Tests

According to NCCN Guidelines for Merkel Cell Carcinoma, the following imaging studies are typically recommended:

PET/CT Scan (18F-FDG PET/CT)

This is a key imaging test that combines a PET scan (which shows metabolic activity) with a CT scan (which shows detailed anatomy). The PET/CT helps doctors:

• Detect if cancer has spread to lymph nodes or distant organs
• Identify metastases (cancer spread) that might not be visible on other scans
• Establish a baseline for comparing future scans

CT Scan of Chest, Abdomen, and Pelvis

This detailed imaging helps evaluate:

• Regional lymph nodes near your tumor
• Potential spread to internal organs
• The extent of disease before treatment planning

MRI (When Appropriate)

MRI may be used in specific situations, particularly for head and neck tumors or when your doctor needs more detailed soft tissue information.

---

Lymph Node Evaluation

Sentinel Lymph Node Biopsy (SLNB)

This is a crucial procedure according to NCCN Guidelines. Here's how it works:

What it is: A surgical procedure where your doctor identifies and removes the first lymph node(s) that cancer would likely spread to from your tumor site.

Why it matters:

• Provides accurate staging information
• Helps predict prognosis (outlook)
• Guides treatment decisions
• Studies show it's associated with improved survival outcomes

The process:

1. A radioactive tracer is injected near your tumor
2. Imaging (lymphoscintigraphy) identifies which lymph nodes "light up"
3. During surgery, the surgeon removes these sentinel nodes
4. Pathologists examine them under a microscope for cancer cells

---

Pathology & Biomarker Testing

Immunohistochemistry (IHC) Staining

Your tumor sample will be tested with special stains to confirm MCC diagnosis and evaluate:

• Cytokeratin 20 (CK20): Typically positive in MCC
• Thyroid Transcription Factor-1 (TTF-1): Usually negative in MCC (helps distinguish from lung cancer)
• INSM1: A newer, more sensitive marker for MCC diagnosis

Merkel Cell Polyomavirus (MCPyV) Testing

According to NCCN Guidelines, testing for MCPyV antibodies may provide prognostic information:

• Patients with high antibody levels to MCPyV T antigens may have better clinical outcomes
• This helps your doctor understand your immune response to the cancer

Circulating Tumor DNA (ctDNA)

This emerging test detects cancer DNA fragments in your blood. Recent research shows ctDNA can:

• Detect recurrence earlier than imaging
• Help monitor treatment response
• Provide prognostic information

---

Blood Tests

Standard blood work typically includes:

• Complete blood count (CBC): Checks red blood cells, white blood cells, and platelets
• Comprehensive metabolic panel: Evaluates kidney and liver function (important before treatment)
• Lactate dehydrogenase (LDH): May provide prognostic information

---

Additional Considerations

Brain MRI

According to NCCN Guidelines, baseline brain imaging has low diagnostic yield in most MCC patients and is not routinely recommended unless you have specific symptoms suggesting brain involvement.

Tumor Size & Depth Measurement

Your pathology report will document:

• Tumor thickness (depth of invasion)
• Tumor size
• Presence of vascular invasion (cancer in blood vessels)

These measurements are important prognostic factors that influence treatment recommendations.

---

Questions to Ask Your Oncology Team

1. Based on my tumor characteristics, what is my stage?
2. Do you recommend sentinel lymph node biopsy, and if so, when?
3. Will I need PET/CT imaging, and how often will I be scanned?
4. What do my pathology results show about prognostic factors?
5. Should I have circulating tumor DNA testing to monitor for recurrence?
6. What is my follow-up surveillance plan after treatment?

---

Why This Matters

According to NCCN Guidelines, accurate staging through these tests directly influences your treatment plan. Patients with node-negative disease (no cancer in lymph nodes) may have different treatment recommendations than those with node-positive disease. Understanding your complete staging picture helps your team design the most appropriate treatment strategy for your specific situation.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.